share_log

三葉草生物-B：截至2024年6月30日止六個月中期業績公告

CLOVER BIO-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEX ·  Aug 27, 2024 17:06

Summary by Moomoo AI

三葉草生物-B（股份代號：2197）公佈截至2024年6月30日止六個月的中期業績。該期間，公司錄得收入人民幣負10.1百萬元，與2023年同期的257萬元相比大幅下降。其他收入及收益亦由2023年同期的2,510.8百萬元減少至67.1百萬元。期內虧損為95.1百萬元，而上年同期則錄得溢利650.6百萬元。經調整期內虧損為87.3百萬元。現金及銀行結餘由2023年底的1,095.5百萬元減少至829.8百萬元。公司在研發、生產及商業化方面取得進展，特別是RSV候選疫苗SCB-1019在臨床試驗中顯示出積極的初步免疫原性及安全性數據。此外，公司完成了四價流感疫苗AdimFlu-S在中國的批簽發，為秋冬接種季節前的市場准入和分銷做好準備。
三葉草生物-B（股份代號：2197）公佈截至2024年6月30日止六個月的中期業績。該期間，公司錄得收入人民幣負10.1百萬元，與2023年同期的257萬元相比大幅下降。其他收入及收益亦由2023年同期的2,510.8百萬元減少至67.1百萬元。期內虧損為95.1百萬元，而上年同期則錄得溢利650.6百萬元。經調整期內虧損為87.3百萬元。現金及銀行結餘由2023年底的1,095.5百萬元減少至829.8百萬元。公司在研發、生產及商業化方面取得進展，特別是RSV候選疫苗SCB-1019在臨床試驗中顯示出積極的初步免疫原性及安全性數據。此外，公司完成了四價流感疫苗AdimFlu-S在中國的批簽發，為秋冬接種季節前的市場准入和分銷做好準備。
Trimed Grass Biotech-B (stock code: 2197) announced its interim performance for the six months ended June 30, 2024. During this period, the company recorded a negative revenue of RMB 101 million, a significant decrease compared to RMB 2.57 million in the same period of 2023. Other income and gains also decreased from RMB 2,510.8 million in the same period of 2023 to RMB 67.1 million. The loss for the period was RMB 95.1 million, while a profit of RMB 650.6 million was recorded in the same period of the previous year. The adjusted loss for the period was RMB 87.3 million. Cash and bank balances decreased from RMB 1,095.5 million at the end of 2023 to RMB 829.8 million. The company made progress in research, production, and commercialization, especially with the RSV candidate vaccine SCB-1019 showing positive initial immunogenicity and safety data in clinical trials. In addition, the company completed the batch issuance of the quadrivalent influenza vaccine AdimFlu-S in China, preparing for market access and distribution before the autumn and winter vaccination season.
Trimed Grass Biotech-B (stock code: 2197) announced its interim performance for the six months ended June 30, 2024. During this period, the company recorded a negative revenue of RMB 101 million, a significant decrease compared to RMB 2.57 million in the same period of 2023. Other income and gains also decreased from RMB 2,510.8 million in the same period of 2023 to RMB 67.1 million. The loss for the period was RMB 95.1 million, while a profit of RMB 650.6 million was recorded in the same period of the previous year. The adjusted loss for the period was RMB 87.3 million. Cash and bank balances decreased from RMB 1,095.5 million at the end of 2023 to RMB 829.8 million. The company made progress in research, production, and commercialization, especially with the RSV candidate vaccine SCB-1019 showing positive initial immunogenicity and safety data in clinical trials. In addition, the company completed the batch issuance of the quadrivalent influenza vaccine AdimFlu-S in China, preparing for market access and distribution before the autumn and winter vaccination season.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated